Repeated autologous umbilical cord blood infusions are feasible and had no acute safety issues in young babies with congenital hydrocephalus.

Sun, Jessica M; Grant, Gerald A; McLaughlin, Colleen; Allison, June; Fitzgerald, Anne; Waters-Pick, Barbara; Kurtzberg, Joanne

Repeated autologous umbilical cord blood infusions are feasible and had no acute safety issues in young babies with congenital hydrocephalus.

dc.contributor.author	Sun, Jessica M
dc.contributor.author	Grant, Gerald A
dc.contributor.author	McLaughlin, Colleen
dc.contributor.author	Allison, June
dc.contributor.author	Fitzgerald, Anne
dc.contributor.author	Waters-Pick, Barbara
dc.contributor.author	Kurtzberg, Joanne
dc.date.accessioned	2022-03-23T19:17:22Z
dc.date.available	2022-03-23T19:17:22Z
dc.date.issued	2015-12
dc.date.updated	2022-03-23T19:17:22Z
dc.description.abstract	Background Babies with congenital hydrocephalus often experience developmental disabilities due to brain injury associated with prolonged increased pressure on the developing brain parenchyma. Umbilical cord blood (CB) infusion has favorable effects in animal models of brain hypoxia and stroke and is being investigated in clinical trials of brain injury in both children and adults. We sought to establish the safety and feasibility of repeated intravenous infusions of autologous CB in young babies with congenital hydrocephalus. Methods Infants with severe congenital hydrocephalus and an available qualified autologous CB unit traveled to Duke for evaluation and CB infusion. When possible, the CB unit was utilized for multiple infusions. Patient and CB data were obtained at the time of infusion and analyzed retrospectively. Results From October 2006 to August 2014, 76 patients with congenital hydrocephalus received 143 autologous CB infusions. Most babies received repeated doses, for a total of two (n = 45), three (n = 18), or four (n = 4) infusions. There were no infusion-related adverse events. As expected, all babies experienced developmental delays. Conclusion Cryopreserved CB products may be effectively manipulated to provide multiple CB doses. Repeated intravenous infusion of autologous CB is safe and feasible in young babies with congenital hydrocephalus.
dc.identifier	pr2015161
dc.identifier.issn	0031-3998
dc.identifier.issn	1530-0447
dc.identifier.uri	https://hdl.handle.net/10161/24644
dc.language	eng
dc.publisher	Springer Science and Business Media LLC
dc.relation.ispartof	Pediatric research
dc.relation.isversionof	10.1038/pr.2015.161
dc.subject	Humans
dc.subject	Hydrocephalus
dc.subject	Treatment Outcome
dc.subject	Reoperation
dc.subject	Cord Blood Stem Cell Transplantation
dc.subject	Transplantation, Autologous
dc.subject	Retrospective Studies
dc.subject	Feasibility Studies
dc.subject	Developmental Disabilities
dc.subject	Age Factors
dc.subject	Time Factors
dc.subject	Child, Preschool
dc.subject	Infant
dc.subject	Infant, Newborn
dc.subject	North Carolina
dc.subject	Female
dc.subject	Male
dc.title	Repeated autologous umbilical cord blood infusions are feasible and had no acute safety issues in young babies with congenital hydrocephalus.
dc.type	Journal article
duke.contributor.orcid	Sun, Jessica M\|0000-0001-8085-1013
duke.contributor.orcid	Grant, Gerald A\|0000-0002-2651-4603
duke.contributor.orcid	Kurtzberg, Joanne\|0000-0002-3370-0703
pubs.begin-page	712
pubs.end-page	716
pubs.issue	6
pubs.organisational-group	Duke
pubs.organisational-group	School of Medicine
pubs.organisational-group	Clinical Science Departments
pubs.organisational-group	Institutes and Centers
pubs.organisational-group	Pathology
pubs.organisational-group	Pediatrics
pubs.organisational-group	Pediatrics, Hematology-Oncology
pubs.organisational-group	Duke Cancer Institute
pubs.organisational-group	Institutes and Provost's Academic Units
pubs.organisational-group	Initiatives
pubs.organisational-group	Duke Innovation & Entrepreneurship
pubs.organisational-group	Pediatrics, Transplant and Cellular Therapy
pubs.publication-status	Published
pubs.volume	78